Incannex Commences Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of

[admin]

Highlights: Incannex has commenced a Phase 2, Blinded, Placebo Controlled Clinical Trial to Determine the Safety and Effect on Pain and Function of IHL-675A in Patients with Rheumatoid Arthritis. The Phase 2 trial follows a successful Phase 1 trial, where IHL-675A was observed to be well tolerated, and animal studies whereby IHL-675A was observed to reduce inflammatory disease scores to a greater extent than hydroxychloroquine, a common long standing prescription drug for rheumatoid arthritis.Th